Treatment strategy for metastatic gastric cancer in Japan

Kojiro Eto¹, Satoshi Ida¹, Masayuki Watanabe¹, Hideo Baba²

¹Department of Gastroenterological Surgery, Cancer Institute Hospital, Koto-ku, Tokyo 135-8550, Japan.
²Department of Gastroenterological Surgery, Graduate School of Medical Sciences, Kumamoto University, Chuo-ku, Kumamoto 860-0811, Japan.

Correspondence to: Dr. Masayuki Watanabe, Department of Gastroenterological Surgery, Cancer Institute Hospital, 3-8-31, Ariake, Koto-ku, Tokyo 135-8550, Japan. E-mail: masayuki.watanabe@jfcr.or.jp


Abstract

Despite recent progress in diagnostic imaging, gastric cancer (GC) is occasionally found at an advanced stage with distant metastasis. As metastatic GC is difficult to cure, the treatment strategy should be considered individually based on the physical and socioeconomic status of patients as well as on the GC symptoms. The first choice of treatment for metastatic GC is chemotherapy, and several chemotherapeutic regimens for metastatic or recurrent GC have been developed through randomized controlled trials. Ongoing clinical trials will provide novel therapeutic options for patients with metastatic GC in the near future, while individualization of treatment based on detailed molecular information, so-called precision medicine, is eagerly anticipated. In this article, we review recent publications and guidelines focusing on recent progress in the treatment of metastatic GC in Japan.

Keywords: Gastric cancer, chemotherapy, molecularly targeted drug, para-aortic lymph node metastasis, liver metastasis

INTRODUCTION

Gastric cancer (GC) is the fourth most commonly diagnosed cancer and the second leading cause of cancer mortality worldwide[1,2]. A large-scale database analysis in the United States revealed that distant metastases were present in 34% of GC patients at the time of their GC diagnosis[3]. Although systematic screening programs have been developed in Japan to enable detection of early stage GC[4], GC is occasionally found at an advanced stage with distant metastasis. The first choice of treatment for patients with metastatic GC is chemotherapy[5]. Although recent advances in chemotherapy, including immune checkpoint inhibitors...
and drugs targeting specific molecular pathways, have achieved an increase in the response rate, it is difficult to cure metastatic GC with chemotherapy alone. The current goals of treatment, therefore, are to relieve GC-related symptoms and to prolong survival. The median survival time achieved in clinical trials for metastatic or recurrent GC remains between 6 and 13 months [6-8], although it has been proven that chemotherapy prolongs survival when compared with the best supportive care (BSC) [9,10]. Recently, it has been reported that curative resection may be performed for patients with liver metastasis, para-aortic lymph node metastasis, or positive peritoneal cytology, especially when chemotherapy has been effective [11-19]. In this review, we summarize the publications and guidelines that have focused on recent progress in the treatment of metastatic GC in Japan.

### TREATMENT STRATEGY FOR METASTATIC GC

The main treatment for metastatic GC is chemotherapy. Table 1 shows the representative trials for metastatic or recurrent GC in Japan. The first chemotherapeutic agent of choice against metastatic GC was 5-fluorouracil (5-FU), which was used either alone or in combination with various agents. In Japan, 5-FU as a key drug for GC was replaced by S-1 (tegafur-gimestat-otastat potassium), based on favorable results in trials involving Japanese patients [8,20]. Thereafter, trials focused on identifying the best combination regimen using S-1. Recently, many drugs designed to target the molecular pathways involved in the development or progression of cancer have been studied for metastatic GC [21-31] [Table 2]. In patients with GC overexpressing human epidermal growth factor receptor 2 (HER2), the addition of trastuzumab, an antibody targeting HER2, to the first-line cytotoxic drug regimens significantly prolonged the survival of patients [21]. Therefore, the presence or absence of HER2 overexpression is the first branch point when selecting the treatment regimen. The recommended treatment algorithm for patients of metastatic GC in the 5th edition of the Japanese Gastric Cancer Treatment Guideline is shown in Figure 1. Recommendation A indicates that the regimen is strongly recommended based on the certain evidence while recommendation B suggests that the regimen is weakly recommended because of insufficient evidence. Figure 2 demonstrates the alternative algorithm for patients who are unfit for the standard treatment due to comorbidities or social situations.

### HER2-negative advanced GC

In Japan, the first choice of chemotherapy for metastatic GC is S-1 and cisplatin (SP), according to the results of a phase III trial (SPIRITS trial [8]). This trial showed that patients treated with SP had significantly better overall survival (OS) than those treated with S-1 alone, with a median OS of 13 vs. 11 months ($P = 0.04$). Progression-free survival (PFS) was also significantly longer in patients treated with SP than in those treated

### Table 1. Results of trials with chemotherapy for metastatic gastric cancer in Japan

<table>
<thead>
<tr>
<th>Authors, year</th>
<th>Regimen</th>
<th>Patients (n)</th>
<th>OS (months)</th>
<th>HR</th>
</tr>
</thead>
<tbody>
<tr>
<td>Koizumi et al. [8], 2008</td>
<td>S-1 + cisplatin</td>
<td>148</td>
<td>13.0</td>
<td>0.77 (0.61-0.98)</td>
</tr>
<tr>
<td></td>
<td>S-1</td>
<td>150</td>
<td>11.0</td>
<td>1</td>
</tr>
<tr>
<td>Yamada et al. [31], 2015</td>
<td>S-1</td>
<td>234</td>
<td>11.4</td>
<td>0.83 (0.68-1.00)</td>
</tr>
<tr>
<td></td>
<td>cisplatin + irinotecan</td>
<td>236</td>
<td>12.3</td>
<td>0.82 (0.68-0.99)</td>
</tr>
<tr>
<td></td>
<td>5-FU continuous infusion</td>
<td>234</td>
<td>10.8</td>
<td>1</td>
</tr>
<tr>
<td>Koizumi et al. [34], 2014</td>
<td>S-1 + docetaxel</td>
<td>314</td>
<td>12.5</td>
<td>0.84 (0.71-0.99)</td>
</tr>
<tr>
<td></td>
<td>S-1</td>
<td>321</td>
<td>10.8</td>
<td>1</td>
</tr>
<tr>
<td>Boku et al. [35], 2009</td>
<td>S-1</td>
<td>234</td>
<td>11.4</td>
<td>0.83 (0.68-1.00)</td>
</tr>
<tr>
<td></td>
<td>cisplatin + irinotecan</td>
<td>236</td>
<td>12.3</td>
<td>0.82 (0.68-0.99)</td>
</tr>
<tr>
<td></td>
<td>5-FU continuous infusion</td>
<td>234</td>
<td>10.8</td>
<td>1</td>
</tr>
<tr>
<td>Narahara et al. [36], 2011</td>
<td>S-1 + irinotecan</td>
<td>155</td>
<td>12.8</td>
<td>0.93</td>
</tr>
<tr>
<td></td>
<td>S-1</td>
<td>160</td>
<td>10.5</td>
<td>1</td>
</tr>
<tr>
<td>Hironaka et al. [44], 2013</td>
<td>Weekly paclitaxel</td>
<td>108</td>
<td>9.5</td>
<td>1.13 (0.86-1.49)</td>
</tr>
<tr>
<td></td>
<td>Weekly irinotecan</td>
<td>111</td>
<td>8.4</td>
<td>1</td>
</tr>
<tr>
<td>Shitara et al. [45], 2017</td>
<td>Tri-weekly nab-paclitaxel</td>
<td>247</td>
<td>10.3</td>
<td>1.06 (0.87-1.31)</td>
</tr>
<tr>
<td></td>
<td>Weekly nab-paclitaxel</td>
<td>246</td>
<td>11.1</td>
<td>0.97 (0.76-1.23)</td>
</tr>
<tr>
<td></td>
<td>Weekly paclitaxel</td>
<td>248</td>
<td>1.06</td>
<td>1</td>
</tr>
</tbody>
</table>

OS: overall survival; HR: hazard ratio; 5-FU: 5-fluorouracil
with S-1 alone, with a median PFS of 6 vs. 4 months ($P < 0.0001$). The response rate of SP in this study was 54%; among 87 patients in the SP group, 46 (52.9%) achieved partial response and 1 (1.1%) had a complete response.
Capecitabine and cisplatin (Cape/CDDP) combination is one of the standard first-line regimens for patients with metastatic or recurrent GC worldwide. Cape/CDDP has been employed as a control regimen in global phase III trials, including the ToGA\textsuperscript{[21]} and AV AGAST trials\textsuperscript{[24]}. The subset analyses of the Japanese participants in these trials have shown safety and efficacy of this regimen; therefore, Cape/CDDP is a first-line treatment choice for Japanese patients.

The REAL-2 trial\textsuperscript{[32]} evaluated whether fluorouracil could be replaced with capecitabine, and cisplatin replaced with oxaliplatin, in the epirubicin, 5-FU and cisplatin (ECF) regimen. This trial demonstrated that capecitabine and oxaliplatin are as effective as 5-FU and cisplatin, respectively, in patients with previously untreated esophagogastic cancer. Cisplatin causes renal toxicity and intravenous hydration is required to decrease the toxicity. Oxaliplatin does not require hydration and can be administered in an outpatient clinic. In Japan, the combination of S-1 plus oxaliplatin (SOX) appears to be as effective as SP for metastatic GC, with a favorable safety profile\textsuperscript{[33]}.

The superiority of a combination of S-1 and docetaxel (DTX) to S-1 monotherapy as first-line treatment was evaluated in the START trial\textsuperscript{[34]} which included Japanese and Korean patients with metastatic or recurrent GC. Although the initial survival analysis failed to demonstrate superiority after clarifying the outcomes of censored cases, a reanalysis demonstrated the efficacy of this regimen [OS 12.5 vs. 10.8 months, hazard ratio (HR) 0.84, 95% CI: 0.71-0.99, \(P = 0.032\)]. Therefore, S-1/DTX can be selected as an alternative to SP, Cape/CDDP, or SOX. Both irinotecan (CPT-11) plus cisplatin and S-1 plus CPT-11 combinations failed to demonstrate survival benefit over 5-FU alone or S-1 alone, and are not recommended as a first-line regimen\textsuperscript{[35,36]}.

Regarding triplet regimens, the V325 trial\textsuperscript{[37]} demonstrated survival benefits of docetaxel, cisplatin, and 5-FU (DCF) over cisplatin and 5-FU (CF), although grade 3 or 4 toxicities were more frequent with DCF than CF. In Japan, a triplet regimen consisting of S-1, cisplatin and docetaxel is currently being evaluated in a phase III trial, JCOG1013, based on the favorable results of a phase II trial in Japan\textsuperscript{[38-40]}.

Based on these findings, the Japanese guidelines recommend SP or Cape/CDDP as first-line treatment of HER2-negative metastatic GC, and SOX, CapeOX, FOLFOX, FP and S-1/DTX are recommended as alternatives.

**HER2-positive advanced GC**

The ToGA trial showed that trastuzumab combined with conventional chemotherapy provided a significant survival advantage compared with chemotherapy alone in patients with HER2 positive metastatic or recurrent GC\textsuperscript{[21]}. A total of 584 patients who had HER2-positive advanced GC or gastroesophageal junction cancer were randomly assigned to chemotherapy (consisting of CF or Cape/CDDP) with or without trastuzumab. The addition of trastuzumab significantly improved OS from 11.1 to 13.8 months (\(P = 0.0046\)), as compared with chemotherapy alone. In addition, PFS increased from 5.5 to 6.7 months (HR 0.7, 95% CI: 0.59-0.85, \(P = 0.0002\)). In the subgroup analysis, the survival benefit was more evident in the group of patients who had immunohistochemistry (IHC) 3+ or IHC 2+/fluorescent in-situ hybridization (FISH)-positive tumors than in the others. The addition of trastuzumab increased survival from 11.8 to 16.0 months (HR 0.65, 95% CI: 0.51-0.83, \(P = 0.036\)) among this cohort. Therefore, trastuzumab is recommended for patients with IHC 3+ or IHC 2+/FISH positive tumors. A phase II trial to explore the efficacy and toxicity of trastuzumab combined with triweekly SP enrolled a total of 56 patients\textsuperscript{[40]}. The response rate and the disease control rate were 68% (95% CI: 54%-80%) and 94% (95% CI: 84%-99%), respectively. The median OS and PFS were 16.0 and 7.8 months, respectively. Major grade 3 or 4 adverse events included neutropenia (36%), anorexia (23%), and anemia (15%). Although the study was not a randomized controlled trial, SP plus trastuzumab is considered to be a first-line chemotherapy choice for HER2-positive metastatic GC in Japan.
Accordingly, the recommended first-line treatment of HER2-positive metastatic GC in Japan is a combination of trastuzumab and Cape/CDDP or a combination of trastuzumab and SP.

Second-line treatment
Second-line chemotherapy is known to prolong the survival of metastatic GC patients, and is recommended for patients with acceptable performance status. Among cytotoxic agents, monotherapy with DTX, CPT-11 or paclitaxel (weekly administration, wPTX) are available options. Randomized trials conducted in Germany and Korea have indicated survival benefits of DTX or CPT-11 over BSC. The German study compared CPT-11 as a second-line chemotherapy with BSC but was ended prematurely due to poor accrual. The median OS was 4.0 vs. 2.4 months in the CPT-11 and placebo arms, respectively ($P = 0.012$). The Korean study compared either CPT-11 or DTX as salvage chemotherapy (SLC) with BSC. The median OS of the SLC and the BSC arms were 5.1 and 3.8 months ($P = 0.004$), respectively. The WJOG4007 compared wPTX with CPT-11 in Japanese patients with advanced GC, after failure of primary combination chemotherapy using fluoropyrimidine plus cisplatin. The median OS of wPTX and CPT-11 groups was 9.5 and 8.4 months, respectively ($P = 0.38$). In addition, third-line chemotherapy was administered in 89.8% of the wPTX group and in 72.1% of the CPT-11 group. Based on these findings, both wPTX and CPT-11 are considered reasonable second-line treatment options for advanced GC.

More recently, two large international phase III trials (REGARD and RAINBOW) have revealed the survival benefits of ramucirumab, a fully human monoclonal antibody against the vascular endothelial growth factor receptor (VEGFR)-2 for previously treated advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma. In the REGARD trial, patients were randomly assigned (2:1) to receive BSC plus either intravenous ramucirumab 8 mg/kg or placebo once every 2 weeks. The median OS was 5.2 months in the ramucirumab group and 3.8 months in the placebo group (HR: 0.77, 95% CI: 0.60-0.99; $P = 0.047$), while the median PFS was 2.1 and 1.3 months, respectively. Ramucirumab appeared to be well tolerated, although rates of hypertension were higher in the ramucirumab group than in the placebo group. The RAINBOW trial compared ramucirumab plus PTX vs. placebo plus PTX in patients with previously treated advanced GC. Patients were randomly assigned in a 1:1 ratio to receive either intravenous ramucirumab 8 mg/kg or placebo on days 1 and 15, plus intravenous PTX 80 mg/m² on days 1, 8, and 15 of a 28-day cycle. OS was significantly longer in ramucirumab plus PTX group than in the placebo plus PTX group (the median OS of 9.6 and 7.4 months, $P = 0.017$). The toxicity of ramucirumab plus PTX was tolerable.

Nab-paclitaxel (nab-PTX) is a nanoparticle-albumin-bound paclitaxel and it does not contain the solvent cremophor EL and ethanol. Therefore, nab-paclitaxel can reduce the risk of a hypersensitivity reaction and can be administered to patients who are intolerant of alcohol. The ABSOLUTE trial is a phase III study to evaluate the efficacy and safety of nab-PTX vs. wPTX in Japanese patients with advanced GC refractory to first-line chemotherapy. The median OS was 10.3 months in the nab-PTX every 3 weeks group, 11.1 months in the weekly nab-PTX group and 10.9 months in the wPTX group. Weekly nab-PTX was non-inferior to wPTX in terms of OS.

In summary, the recommended second-line treatment for metastatic GC in Japan is ramucirumab plus wPTX, and the alternative choice is monotherapy of either DTX, CPT-11, nab-PTX or ramucirumab.

Immune checkpoint inhibitors in GC treatment
The ATTRACTION-2 (ONO-4358-12) trial evaluated the efficacy and safety of nivolumab, a fully human IgG4 monoclonal antibody inhibitor of programmed death-1, in patients with advanced GC or GEJ cancer who had been treated with two or more chemotherapy regimens. The median OS was 5.26 months in the nivolumab group and 4.14 months in the placebo group (HR 0.63, 95% CI: 0.51-0.78; $P < 0.0001$). The
safety profile of nivolumab in patients with advanced GC or GEJ cancer was manageable and similar to
that reported in patients with other advanced solid tumors. Based on these results, the Japanese Ministry of
Health, Labor and Welfare approved nivolumab for the treatment of unresectable advanced or recurrent GC
which has progressed after chemotherapy. Currently, trials are ongoing to evaluate the efficacy of immune
checkpoint inhibitors in earlier lines of GC treatment.

**Ongoing trials in Japan**

The RAINFALL trial is ongoing to evaluate the effectiveness of ramucirumab in combination with Cape/CDDP compared to Cape/CDDP alone as first-line treatment of metastatic GC or GEJ adenocarcinoma (NCT02314117). The SOLAR trial, a phase III trial comparing TAS-118 (S-1 plus leucovorin) and oxaliplatin vs. SP as first-line treatment, is recruiting patients with advanced GC in Japan and Korea (NCT02322593).

**Precision medicine for GC**

Treatment of cancer is likely to shift and be tailored towards personalized therapy based on detailed molecular
information, known as precision medicine. The Cancer Genome Atlas Research Network reported the results
of molecular classification of GC through integrative genomic analysis, which suggested that GC could be
divided into four subtypes:\[47\]: (1) Epstein-Barr virus-related tumors; (2) microsatellite instability represented
as elevated mutation rates and MLH1 silencing; (3) genomically stable tumors that are strongly related with
diffuse histology, RHOA mutations, and CLDN18-ARHGAP fusion; and (4) chromosomal instability that
mainly comprises intestinal histology, TP53 mutation, and focal amplification of the receptor tyrosine
kinase. Another study reported that GC can be classified into four subtypes:\[48\]: (1) microsatellite unstable;
(2) microsatellite stable (MSS) with TP53 mutation; (3) MSS without TP53 mutation; and (4) MSS with
epithelial-to-mesenchymal transition (EMT). This study found that the MSS/EMT subtype was related
to poor prognosis. Further analysis is needed to establish genome-based precision medicine.

**CONCLUSION**

The main goal of treatment for metastatic GC patients is to prolong patient survival while preserving
quality of life. In addition to the combination of conventional cytotoxic drugs, several newly developed
agents, including targeted molecules and immune checkpoint inhibitors, have shown favorable results in
the treatment of metastatic GC. Efforts should be focused on achieving precision medicine based on the
molecular information of GC.

**DECLARATIONS**

**Authors’ contributions**

Concept, design, literature search, and manuscript preparation: Eto K
Manuscript editing: Ida S
Design, manuscript editing, and manuscript review: Watanabe M
Manuscript review: Baba H

**Financial support and sponsorship**

None.

**Conflicts of interest**

Authors declare that they have no conflicts of interest.

**Patient consent**

Not applicable.
REFERENCES


42. Thuss-Patience PC, Kretzschmar A, Bichet D, Deist T, Hinke A, Breithaupt K, Dogan Y, Gebauer B, Schumacher G, Reichardt P. Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer--a randomised phase III


